期刊文献+

气相色谱法测定1-叔丁氧羰基哌嗪中哌嗪的方法学研究

GC Analysis and Methodology Research for Piperazine in 1-(Tert-Butoxycarbonyl)Piperazine
下载PDF
导出
摘要 建立气相色谱法测定1-叔丁氧羰基哌嗪中的哌嗪,该方法使用非极性固定相的气相色谱柱(Agilent CP-Volamine 30 m×0.32 mm)。起始温度为80℃,保持2 min,以20℃/min的速率升温至200℃并保持6 min;检测器温度为300℃;进样口温度为180℃;载气流速为4.0 mL/min。进样体积1μL。哌嗪的定量限为3.2μg/mL,在3.2~80μg/mL的线性函数关系较好,平均回收率为100.94%,回收率RSD为1.3%。本方法的专属性和检测准确度均较好,检测灵敏度较高,可用于1-叔丁氧羰基哌嗪的质量控制。 A GC method has been established for detecting the piperazine in 1-(tert-butoxycarbonyl)piperazine.A non-polar stationary phase gas chromatography column(Agilent CP-Volamine 30 m×0.32 mm)was used.Maintain the column temperature at 80℃for 2 min,than raise temperature at a rate of 20℃/min to 200℃and maintain for 6 min;the temperature of detector is 300℃;the temperature of injetion port is180℃;the flow rate of the carrier gas is 4.0 mL/min.The injection volume is 1μL.The limit of piperazine was 3.2μg/mL,the method was linear from 3.2μg/mL to 80μg/mL,the accuracy was similar with a mean(RSD)ratio of 100.94%(1.3%).The method is specific,accuracy and sensitive,and can be used for the quality control of 1-(tert-butoxycarbonyl)piperazine.
作者 伍鸣亮 张运海 曾海金 罗恒真 Wu Mingliang;Zhang Yunhai;Zeng Haijin;Luo Hengzhen(Jiangxi Qingfeng Pharmaceutical Co.,Ltd.,Ganzhou 341000,China)
出处 《山东化工》 CAS 2022年第7期105-107,共3页 Shandong Chemical Industry
关键词 气相色谱法 1-叔丁氧羰基哌嗪 哌嗪 方法学 GC 1-(tert-butoxycarbonyl)piperazine piperazine analytical validation
  • 相关文献

参考文献4

二级参考文献34

  • 1冯桂荣,张相平,张会茹,张建维.双芳基脲衍生物的合成[J].河北化工,2005,28(5):34-35. 被引量:6
  • 2Keith J M, Apodaca R, Xiao W, et al. Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase [J ]. Bioorganic & Medicinal Chemistry Letters, 2008, 18 (17) : 4 838-4 843. 被引量:1
  • 3Glamkowski E, Reitano P, Woodward D L. Synthesis and evaluation of 3-aubstituted 1-[4-(2-indol-3-ylethyl) piperazinyl ] ureas as potential antihypertensive agents [J ]. Journal of Pharmaceutical Sciences, 1978, 67 (12) : 1 773-1 774. 被引量:1
  • 4FDA. LYNPARZA [EB/OL]. [ 2014-12-19 ] ( 2015-02-02 ). http://www, accessdata, fda. gov/drugsatfda_ docs/label/ 2014/2061621bl. pdf. 被引量:1
  • 5Althaus FR,Richter C. ADP-ribosylation of proteins: enzy- mology and biological signiaieance[J]. Mol Biol Biochem Bio- phys,1987,37(1) :1-237. 被引量:1
  • 6Domehek SM,Weber BL. Clinical management of BRCA1 and BRCA2 mutation carriers[J]. Oneogene, 2006, 25(43), 5825-6831. 被引量:1
  • 7Moynahan ME,Chiu JW, Koller BH, et al. BRCA1 controls homology-directed DNA repair [J]. Mol Cell, 1999,4 (4) : 511-518. 被引量:1
  • 8Tutt A, Bertwistle D, Valentine J, et al. Mutation in BRCA2 stimulates crror-prone homology-directed repair of DNA double-strand breaks occurring between repeated se- quenced[J]. EMBO J, 2001,20(17) :4704-4716. 被引量:1
  • 9Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant ceils as a therapeutic strategy [J]. Nature, 2005, 434(7035):917-921. 被引量:1
  • 10Bundred N, Gardovskis J, Jaskiewicz J,et al. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP in- hibitor olaparib: a phase I multicentre trial in patients sched- uled for elective breast cancer surgery I Jl. Invest New Drugs, 2013, 31 (4): 949-958. 被引量:1

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部